Caladrius Biosciences to Host First Quarter 2021 Financial Results Conference Call on Thursday, May 6, 2021 at 4:30 p.m. Eastern Time
April 29, 2021 08:30 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s Disease
March 08, 2021 08:00 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., March 08, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences to Present at the H.C. Wainwright Global Life Sciences Virtual Conference
March 03, 2021 08:30 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
February 25, 2021 16:05 ET
|
Caladrius Biosciences, Inc.
Company demonstrates resilience despite COVID-19 challenges: Financial situation secure and development programs progressing Conference call begins today at 4:30 p.m. (ET) BASKING RIDGE, N.J., Feb. ...
Caladrius Biosciences to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Thursday, February 25, 2021 at 4:30 p.m. Eastern Time
February 18, 2021 16:05 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences, Inc. Closes $65 Million Registered Direct Offerings Priced At-The-Market under Nasdaq Rules
February 17, 2021 13:59 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences, Inc. Announces $65 Million Registered Direct Offerings Priced At-The-Market under Nasdaq Rules
February 12, 2021 08:15 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences Closes $25.0 Million Private Placement
January 25, 2021 17:05 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences Announces Participation in Upcoming Virtual Conferences in February 2021
January 25, 2021 08:30 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences Announces $25.0 Million Private Placement
January 21, 2021 09:00 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...